{"transactions":[{"id":846358,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-12T20:15:16.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104721","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526104721/ownership.xml","form_type":"4"}},{"id":846357,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T20:15:16.000Z","date":"2026-03-10","kind":"purchase","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104721","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526104721/ownership.xml","form_type":"4"}},{"id":910105,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910104,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910103,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910102,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910101,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910100,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910099,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910098,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":910097,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T16:30:14.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312526046670/ownership.xml","form_type":"4"}},{"id":1023426,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1352200},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023425,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":550323},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023424,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":124085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023423,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":124085,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":124085,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023422,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":607536,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":607536},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023421,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":1656789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":1656789},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023420,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37700,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509780},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023419,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":330194},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023418,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":186128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023417,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":186128,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":186128,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023416,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023415,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2384873,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023414,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":182,"price":6.75,"value":1228.5,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2384873,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023413,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":124085,"price":0.01,"value":1240.85,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2385055,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023412,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":900,"price":6.75,"value":6075.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2260970,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023411,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":607536,"price":0.01,"value":6075.36,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2261870,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023410,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":2455,"price":6.75,"value":16571.25,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1654334,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023409,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":1656789,"price":0.01,"value":16567.89,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023408,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":674554,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023407,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":6.75,"value":1863.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674554,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023406,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":186128,"price":0.01,"value":1861.28,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674830,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023405,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488702,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1023404,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T17:51:29.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488982,"source":{"system":"sec-edgar","filing":"0001193125-25-232138","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000119312525232138/ownership.xml","form_type":"4"}},{"id":1392227,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T18:40:17.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":185595,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":556782,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":185595},"source":{"system":"sec-edgar","filing":"0000950170-24-112617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024112617/ownership.xml","form_type":"4"}},{"id":1392226,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T18:40:17.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024112617/ownership.xml","form_type":"4"}},{"id":1405307,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-17T20:17:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":25142840,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2091383},"source":{"system":"sec-edgar","filing":"0000950170-24-107542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024107542/ownership.xml","form_type":"4"}},{"id":1405306,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-17T20:17:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":12299854,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1023103},"source":{"system":"sec-edgar","filing":"0000950170-24-107542","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024107542/ownership.xml","form_type":"4"}},{"id":1405305,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T20:17:16.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3614486,"source":{"system":"sec-edgar","filing":"0000950170-24-107542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024107542/ownership.xml","form_type":"4"}},{"id":1405304,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T20:17:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2091383,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3114486,"source":{"system":"sec-edgar","filing":"0000950170-24-107542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024107542/ownership.xml","form_type":"4"}},{"id":1405303,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T20:17:16.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1023103,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1023103,"source":{"system":"sec-edgar","filing":"0000950170-24-107542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024107542/ownership.xml","form_type":"4"}},{"id":1536255,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T17:00:16.000Z","date":"2024-04-22","kind":"purchase","planned":false,"acquired":true,"shares":17857,"price":56,"value":999992.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on April 22, 2024 pursuant to a Subscription Agreement dated April 17, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1090793,"source":{"system":"sec-edgar","filing":"0000950170-24-047680","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024047680/ownership.xml","form_type":"4"}},{"id":1543890,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T19:30:56.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":371187,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":371187,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":371187},"source":{"system":"sec-edgar","filing":"0000950170-24-043495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024043495/ownership.xml","form_type":"4"}},{"id":1543889,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-04-10T19:30:56.000Z","date":"2024-04-08","kind":"purchase","planned":false,"acquired":true,"shares":123729,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":123729,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":123729},"source":{"system":"sec-edgar","filing":"0000950170-24-043495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000095017024043495/ownership.xml","form_type":"4"}},{"id":1702358,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-12-21T17:05:33.000Z","date":"2023-12-19","kind":"purchase","planned":false,"acquired":true,"shares":175525,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"derivative":{"exercise_price":0.01,"exercise_date":"2023-12-20","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":175525},"source":{"system":"sec-edgar","filing":"0001209191-23-059458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919123059458/doc4.xml","form_type":"4"}},{"id":1751462,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-11-02T18:56:47.000Z","date":"2023-10-31","kind":"purchase","planned":false,"acquired":true,"shares":100606,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1481264,"derivative":{"exercise_price":0.01,"exercise_date":"2023-11-01","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":100606},"source":{"system":"sec-edgar","filing":"0001209191-23-054222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919123054222/doc4.xml","form_type":"4"}},{"id":1777461,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-09-19T18:32:11.000Z","date":"2023-09-15","kind":"purchase","planned":false,"acquired":true,"shares":552263,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1380658,"derivative":{"exercise_price":0.01,"exercise_date":"2023-09-18","expiration_date":"2028-08-29","underlying":"Common Stock","underlying_shares":552263},"source":{"system":"sec-edgar","filing":"0001209191-23-050074","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919123050074/doc4.xml","form_type":"4"}},{"id":1806054,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2023-08-16T08:59:43.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":828395,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Warrants to be issued pursuant to the Warrantholders Agreement and the Credit Agreement, dated August 4, 2023, between the Issuer and NEA 18 VGE."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Warrantholders Agreement (\"Warrantholders Agreement\"), dated August 4, 2023, between the Issuer and NEA 18 Venture Growth Equity L.P. (\"NEA 18 VGE\"), the warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual (such date, the \"Closing Date\"). The warrants will be exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 VGE, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":828395,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":828395},"source":{"system":"sec-edgar","filing":"0001209191-23-045956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919123045956/doc4.xml","form_type":"4"}},{"id":1827051,"issuer":{"id":4900,"kind":"organization","name":"Savara Inc","symbol":"SVRA"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T23:13:26.000Z","date":"2023-07-17","kind":"purchase","planned":false,"acquired":true,"shares":333333,"price":3,"value":999999.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"). NEA 17 is the sole member of Growth Equity Opportunities 17, LLC (\"GEO 17\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by GEO 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":24471264,"source":{"system":"sec-edgar","filing":"0001209191-23-042805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1160308/000120919123042805/doc4.xml","form_type":"4"}},{"id":2134859,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-19T20:05:16.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":100000,"price":1000,"value":100000000.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":70574720},"source":{"system":"sec-edgar","filing":"0001209191-22-054148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919122054148/doc4.xml","form_type":"4"}},{"id":2134858,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2022-10-19T20:05:16.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":37700,"price":1000,"value":37700000.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") is convertible at the option of the holder (subject to the expiration or early termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended) into the number of shares of the Issuer's common stock (\"Common Stock\") equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 plus increases for accumulated quarterly dividends that are not paid in cash (\"compounded dividends\")) plus (ii) the accrued dividends with respect to each share of Series B Preferred Stock as of the applicable conversion date divided by (b) the conversion price as of the applicable conversion date (initially approximately $1.4169), subject to anti-dilution adjustments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock has no expiration date. At any time after the third anniversary of the original issuance date, if the closing price per share of Common Stock is greater than 287% of the then applicable conversion price (initially $4.07) for (x) at least 20 trading days in any period of 30 consecutive trading days and (y) the last trading day immediately before the Issuer provides notice of its election to convert, the Issuer may elect to convert all of the Series B Preferred Stock into the relevant number of shares of Common Stock. [Continued on Note 3]"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"[Continuation of Note 2] At any time following the fifth anniversary of the original issuance date, the Issuer may redeem all of the Series B Preferred Stock for a per share amount in cash equal to: (i) the sum of (A) the liquidation preference (reflecting increases for compounded dividends) thereof plus (B) all accrued dividends as of the applicable redemption date, multiplied by (ii) (A) 105% if the redemption occurs at any time prior to the seventh anniversary of the original issuance date and (B) 100% if the redemption occurs at any time on or after the seventh anniversary of the original issuance date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":37700,"derivative":{"underlying":"Common Stock","underlying_shares":26606669},"source":{"system":"sec-edgar","filing":"0001209191-22-054148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919122054148/doc4.xml","form_type":"4"}},{"id":2650460,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C convertible preferred Stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":2361912,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":669002},"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650459,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":11500000,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3257328},"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650458,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 convertible preferred stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":9588725,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2715968},"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650457,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"purchase","acquired":true,"shares":1050000,"price":19,"value":19950000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":7692298,"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650456,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":669002,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6642298,"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650455,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":3257328,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5973296,"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}},{"id":2650454,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":61265,"kind":"person","name":"Yang Rick","position":1,"cik":"0001851328","reported_name":"Yang Rick","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:09:39.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":2715968,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2715968,"source":{"system":"sec-edgar","filing":"0001209191-21-044051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851328/000120919121044051/doc4.xml","form_type":"4"}}]}